Visit our new Alternative Investment section.Click here
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sorry to be so ignorant but what has happened to this company. Is it still trading?
has been a pretty **** 5 year investment.
that much closer to some actual positive payouts/news but the market doesn't give a toss.
problem is investors have given up on aim and bent directors. (i'm not talking about nsci)
our lot need to send out a clear message with the results.
they are committed to our listing.
they won't do any more placings until we have a substantial improvement in the sp.
start the wheels turning to prepare for a buy back as funds come in.
across the board director buying post results.
buying our shares at 55p vs £2.00 is better than having to wait another 5/10 years for some new blue sky to come good.
make or break time for nsci/glycotest/qbot and a few others over the next 6 months.
hopefully it will be worth the wait.
EMV CAPITAL-BACKED GLYCOTEST™ PARTNERS WITH UNIVERSITY OF GEORGIA TO ACCELERATE NOVEL LIVER CANCER DIAGNOSTIC ASSAYS
SEPTEMBER 23, 2024-NEWS - NO COMMENTS - POSTED BY WEBMASTER
Merion, PA – 23 September 2024 – Glycotest, Inc. announces that it has entered into an agreement with the University of Georgia Complex Carbohydrate Research Center (CCRC) in Athens, GA to develop novel glycomic assays for its HCC Panel blood test, aimed at early-stage liver cancer detection. The agreement moves Glycotest towards commercializing its breakthrough platform, leveraging significant R&D efforts to tackle Hepatocellular Carcinoma (HCC), the most common and lethal form of liver cancer.
Under the terms of the agreement, Glycotest will fund the development of the new assays at the CCRC, with Glycotest securing exclusive rights to the resulting intellectual property. The new assays developed by the CCRC will be deployed by Glycotest in its HCC Panel test. The assay development work will be spearheaded by Dr. Parastoo Azadi, Associate Director of CCRC Service and Training.
Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company has made huge strides in developing its innovative diagnostic technology and the deal with CCRC, a world leader in glycoscience, marks a crucial step toward market launch.
Charles Swindell, PhD, CEO, Glycotest, commented:
“Glycotest is fortunate to partner with the CCRC—a world renowned innovator in glycoscience testing methodology—on this final chapter in making the HCC Panel test available to liver disease patients and their physicians. We believe the HCC Panel could become a significant tool for better identification of early-stage HCC patients eligible for potentially curative therapy.”
The CCRC’s expertise will enhance Glycotest’s proprietary HCC Panel, which has already shown promise in identifying early-stage liver cancer—where treatment options can be most effective. The potential market is huge, with an estimated three million patients in the US, and potentially up to 380 million patients worldwide, eligible for routine HCC surveillance testing. Glycotest employs unique non-invasive blood tests based on proprietary serum glycoprotein biomarkers, biomarker panels and assay technology that exploit novel carbohydrate-based disease signal chemistry.
The CCRC is a long-standing center of excellence in the glycosciences, the branch of science that investigates the structure, biosynthesis, and biological functions of molecules that contain carbohydrates. With expertise and resources in a rich array of sophisticated instrumental techniques key to glycoscience research, the CCRC is uniquely positioned to collaborate with Glycotest on this important project focusing on the development of superior mass spectroscopy-based glycomic assays.
Parastoo Azadi, PhD, Associate Director of the CCRC-Service and T
New Website on the way!
13 September 2024
Hello and thanks for visiting! We’re currently in the process of updating our website to make it even better for you. We're enhancing our features, improving our content, and ensuring you have an even more seamless experience.
During this period, some parts of the site may be temporarily unavailable, and we appreciate your patience and understanding. If you need immediate assistance, please feel free to reach out to us through our contact page.
Stay tuned for our new look
Started: Shanders20, 13 Sep 2024 11:02
Last post: Louis_Winthorp, 13 Sep 2024
There's been little share price excitement here since June - November 2021.
Continues to baffle me why shares have fallen so far back .Thanks for highlighting report will take a look
Http://www.glycotest.com/wp-content/uploads/2024/08/Glycotest-Presentation-ws-240827.pdf
Glycotest valued at zero in the SP if anyones still holding!
Looks like a brand new 36 page presentation has just been uploaded to the Glycotest website.
The puss take continues.
The market cap is taken care of by Qbot, PDSB and ProAxis alone.
The fund manager is with a minimum of £10M
In Theory Glycotest is worth £10M+
Plus 20 other stakes worth £10M+
Lets hope they get their shXt together when they come back from holiday.
12 August 2024
London, UK: Q-Bot, a leading provider of innovative underfloor insulation solutions with robots, is delighted to announce a strategic partnership with Furbnow, who are dedicated to decarbonising 1 million UK homes by 2030. This collaboration will see Q-Bot’s advanced underfloor insulation (UFI) technology integrated into Furbnow’s comprehensive Home Energy Plans, helping homeowners across the country enhance comfort and reduce energy consumption.
Q-Bot robot in floor void with Furbnow and Q-Bot logos
Furbnow, known for its comprehensive, end-to-end approach to home energy upgrades, offers homeowners a one-stop shop for retrofitting their properties. By combining forces with Q-Bot, Furbnow will further streamline its supply chain management, ensuring that homeowners receive the highest quality insulation solutions available.
Becky Lane, CEO at Furbnow, commented on the partnership, “We are excited to welcome Q-Bot into the Furbnow family. Their innovative underfloor insulation technology is a game-changer for homeowners looking to improve the energy efficiency of their homes. Together, we’re not just offering insulation – we’re providing peace of mind and long-term savings, all while contributing to our goal of decarbonising 1 million UK homes by 2030.”
Leigh Fairbrother, Head of Commercial at Q-Bot, added, “Partnering with Furbnow is a significant step in our mission to make UK homes warmer, healthier, and more energy efficient. We share a commitment to delivering energy efficiency measures with the highest level of quality assurance. By integrating our UFI technology into Furbnow’s Home Energy Plans, we can help more homeowners across the UK reduce their energy consumption and mitigate the risks of damp and mould.”
This partnership underscores the shared vision of both companies to lead the charge in the decarbonisation of UK homes, providing innovative, tailored solutions that enhance the quality of living for homeowners across the country.
If they monetise something seriously, folks will look. Until then, and with the anchor investment performing poorly, it ain't going to move.
We are off it unfortunately
RNS out
Earlier today.
Have NSCI given up on the PR?
PRESS RELEASE: E.ON and Q-Bot team up to use robotics and AI to help insulate Britain’s homes
Leading energy and solutions provider E.ON and construction tech firm Q-Bot Ltd are joining forces to help insulate Britain’s homes – using the power of robotics and AI. The companies are working in partnership with the government under the Great British Insulation Scheme (GBIS) to offer an average of £1,3771 in funding for Q-Bot to install ground-breaking underfloor insulation in qualifying homes across the UK.
Alexis Keel, E.ON UK’s Head of Obligation Delivery , said: “Improved insulation makes for more comfortable homes and healthier residents, and we’re proud to work with Q-Bot to help make this a reality for even more people across the country. Q-Bot’s unique approach mirrors our own ambition to create a new energy world where affordability, innovation and sustainability go hand-in-hand as we work to meet the nation’s net zero goals.”
Leigh Fairbrother, Q-Bot’s Head of Commercial, said: “We are delighted to be working with E.ON to help improve the energy efficiency of homes across the country. We already install our floor insulation in more than 100 British homes every month and together with E.ON, we can help in the delivery of the Government’s insulation policy and fuel poverty agenda and improve the fabric of the country’s housing stock, especially in the social housing sector. Importantly, , our insulation can make homes healthier, by reducing the risk of damp and mould, as well as making a positive impact on comfort for people up and down the country.”
About the E.ON and Q-Bot scheme
The first phase of the E.ON Next and Q-Bot GBIS partnership will run in the North East and the South East of England, South Wales and London. If successful, the scheme could extend across England, Scotland and Wales over the next two years.
GBIS forms part of the broader energy efficiency programme which it delivers under the auspices of OFGEM’s Energy Company Obligation (ECO), a requirement for all large energy suppliers. E.ON and Q-Bot hope to insulate hundreds of homes as part of the scheme, as either a single energy efficiency measure or part of a comprehensive energy efficiency upgrade of a
When NSCI released their results in early June the price for PDSB was $2.97 (3.5%) taken on the 30th May 24 for going concern/accounts purposes.
As of today they have another £1M on the balance sheet to play with.
Today a pause in the recent gradual rise.
The same day that over in the US it looks as if short interest in
PDSB is decreasing
PDSB is on 30-40 months for OS.
MRK alternative just hit the buffers!
Frank holding all the cards for a full partnership or buyout.
24-Jun-2024 / 19:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients with unresected locally advanced head and neck cancer in a phase III clinical trial (TrilynX). The company decided to discontinue this study. The decision follows a pre-planned interim analysis performed by the study’s Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Given the totality of the data, the company decided to also stop the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy in patients who underwent resection of locally advanced head and neck cancer).
Started: biffa, 22 Jun 2024 09:25
Last post: Shanders20, 24 Jun 2024
No buy quote. Tried several times with differing amounts - nothing above 5K. I could leave buy order to try and be filled but not in realtime.
I agree Oak Bloke has certainly carried out some detailed research on Martlet for other readers see here -
https://theoakbloke.substack.com/p/martlet-capital-part-of-nsci?
It's good news. MMS are short of stock for you to buy but are happy to take them onto their books.
NMS is quite small in NSCI, but they should at least offer that with a buy quote.
How many were you trying for? Perhaps split into 5K batches.
Oak bloke has done a decent write up on the Martlet portfolio (Part 1)
Yet again shows the crazy value gap.
Started: biffa, 17 Jun 2024 18:52
Last post: Shanders20, 21 Jun 2024
I tried to buy shares today via Ii and could only leave a buy order no live quote offered - but I could sell shares !! Any ideas why this should be ….
A new article - ‘A below the radar investment company on a bargain rating’ - published by Simon Thompson / IC today.
Started: biffa, 17 Jun 2024 18:50
Last post: biffa, 17 Jun 2024
Just to add to the feel good factor!
NetScientific: Broker initiates coverage with 'buy' recommendation and 137p price target
Published: 14:58 17 Jun 2024 BST
NetScientific PLC -
Panmure Gordon has initiated coverage on NetScientific PLC (AIM:NSCI) with a 'buy' recommendation and a price target of 137 pence, hailing its shift away from traditional venture capital (VC) investment models towards a focus on deep technology and life sciences sectors.
NetScientific, under the leadership of CEO Dr Ilian Iliev since 2020, has evolved to support innovation and growth in these sectors, the broker said.
The company’s strategy includes syndicating third-party investments and offering advisory services to its portfolio companies. These services generate additional revenue, helping offset the costs of managing the platform, Panmure said.
Its assets under management (AUM) have grown substantially, from approximately £12 million in 2020 to over £100 million. This advance is a mix of direct investments and managed third-party holdings, the broker said in its initiation report.
A key aspect of NetScientific's strategy is its focus on areas such as artificial intelligence (AI), robotics, semiconductors, materials science, and life sciences. This approach marks a departure from traditional VC investments in software as a service (SaaS), digital-only models, and fintech, Panmure said.
A notable example of NetScientific’s strategic shift is the recent deal between its subsidiary EMV Capital and Cambridge-based Martlet Capital. This transaction significantly increased AUM and is expected to enhance revenue opportunities and support future fund launches.
As NetScientific continues to execute its strategy, it leverages its exposure to high-barrier-to-entry businesses across various subsectors. This diversification presents numerous opportunities for value creation.
Panmure Gordon’s valuation of NetScientific at £32.8 million, or 137p per share, represents a 98% potential upside from current levels.
In afternoon trading the stock was up 1% at 70.9p.
I can only see a steady climb from here as the penny profit brigade finally fook off and leave us to it.
Decent questions from Colin,Neil,Graham and Simon yesterday (and me).
At last we have an up to date line in the sand valuation of £40M that we can add/subtract to as news comes in.
If they don't get the SP up we might be on the receiving end of a bid ourselves!
Mr Kight, HNW individual has just disclosed over 3%.
Holds 8% of Tekcapital (TEK) His holding worth £2M. TEK invests in spinning out university IP.
Let's hope he sees more value here and continues to add.
One of our Martlet Investments. £29M!
Echion raises £29 million in Series B investment round
June 14, 2024
Series B fundraise of £29 million led by Volta Energy Technologies with CBMM, BGF and Cambridge Enterprise Ventures
The world’s leading developer of niobium-based, fast-charging battery materials, Echion Technologies, has successfully completed its Series B funding round, raising £29 million in investment capital. The round was led by specialist battery and energy storage technology investor Volta Energy Technologies (Volta), with participation from existing investors CBMM, BGF, and Cambridge Enterprise Ventures.
The investment will enable Echion to execute its go-to-market strategy to see its innovative niobium-based XNO® anode material utilised in real world applications, at volume. Echion is Volta’s first investment into a European headquartered company and having Volta as the lead Series B investor highlights Echion as a rising British battery technology business within the crucial global energy storage industry.
Echion’s longstanding partnership with the world’s leading producer of niobium, CBMM, will see the opening of a 2,000 tonne per year XNO® manufacturing facility this year. This provides Echion with the manufacturing capacity to satisfy the large and growing demand for XNO® across its global customer base comprised of major cell manufacturers and original equipment manufacturers (OEMs).
Great results and a pretty good presentation that answered most of the questions.
3 out of 4 on the wish list so not to bad.
Decent involvement from a number of people.
Panmure note on it's way which would be a first.
£35.6M plus £4M since year end so £40M vs £15M.
No reason for this not to steadily move higher as news flow and investor interest increases.
Started: Troajan, 13 Jun 2024 11:39
Last post: mornington-oz, 14 Jun 2024
RNS OUT
Started: biffa, 13 Jun 2024 07:59
Last post: philg65, 13 Jun 2024
I agree but the market thinks differently. I believe that they're expecting more concrete news for Glycotest.
A positive set of results with more to come.
It does nothing because the UK marlet is investment market is weak and uk investors are littered with traders that can't add up.
Emv and Netscientific are doing a fantastic job raising sufficient capital to allow businesses to grow from acorns to large trees. They will exit some of these in due course and every one will then realise what they missed out on.
Results day tomorrow which will highlight how undervalued we are. Not expecting markets to get it as investors would sooner put money abroad in companies valued at 100's times sales because some push this as a good idea whereas investing at a third of NAV is a better investment all day long in my opinion
The whole problem is its all totally illiquid save PDBS which is on the floor at $2.7.
Continual funding here and there does nothing. They need to have some healthy crystallisations for even a modest rise.
Loads of news coming out from PointGrab so worth keeping an eye on.
New website and sales team doing quite well.
Selected partners may offer promotions for new customers. We may earn a referral fee if you open an account
Follow the stocks
that matter to you
Create a free LSE account to:
Already a member? Log in
Create Free Account

